公开(公告)号：US08853437B2

公开(公告)日：2014-10-07

申请号：US13202489

申请日：2010-02-19

申请人： Makoto Arita ,  Hiroyuki Arai ,  Yousuke Isobe ,  Ryo Taguchi

发明人： Makoto Arita ,  Hiroyuki Arai ,  Yousuke Isobe ,  Ryo Taguchi

IPC分类号： C07C59/42 ,  C07C233/09 ,  A61K31/16 ,  A61K31/11 ,  C07C291/00 ,  C12P7/64

CPC分类号： C07C59/42 ,  C12P7/6427 ,  C12P7/6436

摘要： An object of the present invention is to provide a compound having a novel structure for overcoming the defects of conventional steroid agents and NSAIDs. It is found that the particular dihydroxy bodies of eicosapentaenoic acid and docosahexaenoic acid, which have not conventionally been known (11,18-dihydroxy eicosapentaenoic acid (11,18-diHEPE), 17,18-dihydroxy eicosapentaenoic acid (17,18-diHEPE) etc.), have activity of inhibiting neutrophil, thereby solving the object. The present invention unexpectedly remarkably inhibits infiltration into a tissue of, and activation of neutrophil found out at acute inflammation. The compound of the present invention is a compound which has not conventionally been known. Therefore, utility as a new therapeutic is provided.

摘要翻译： 本发明的目的是提供一种具有克服常规类固醇剂和NSAID缺陷的新颖结构的化合物。 已经发现，二十碳五烯酸和二十二碳六烯酸的二羟基体通常不是已知的（11,18-二羟基二十碳五烯酸（11,18-diHEPE），17,18-二羟基二十碳五烯酸（17,18-diHEPE ）等）具有抑制嗜中性粒细胞的活性，从而解决了对象。 本发明意外地显着地抑制了在急性炎症中发现的组织和嗜中性粒细胞的活化。 本发明的化合物是通常未知的化合物。 因此，提供了作为新治疗剂的效用。

公开(公告)号：US20120059061A1

公开(公告)日：2012-03-08

申请号：US13202489

申请日：2010-02-19

申请人： Makoto Arita ,  Hiroyuki Arai ,  Yousuke Isobe ,  Ryo Taguchi

发明人： Makoto Arita ,  Hiroyuki Arai ,  Yousuke Isobe ,  Ryo Taguchi

IPC分类号： A61K31/202 ,  C12P7/42 ,  A61P15/06 ,  A61P11/00 ,  A61P1/04 ,  A61P35/00 ,  C07C57/03 ,  A61P9/10

CPC分类号： C07C59/42 ,  C12P7/6427 ,  C12P7/6436

摘要： An object of the present invention is to provide a compound having a novel structure for overcoming the defects of conventional steroid agents and NSAIDs. It is found that the particular dihydroxy bodies of eicosapentaenoic acid and docosahexaenoic acid, which have not conventionally been known (11,18-dihydroxy eicosapentaenoic acid (11,18-diHEPE), 17,18-dihydroxy eicosapentaenoic acid (17,18-diHEPE) etc.), have activity of inhibiting neutrophil, thereby solving the object. The present invention unexpectedly remarkably inhibits infiltration into a tissue of, and activation of neutrophil found out at acute inflammation. The compound of the present invention is a compound which has not conventionally been known. Therefore, utility as a new therapeutic is provided.

摘要翻译： 本发明的目的是提供一种具有克服常规类固醇剂和NSAID缺陷的新颖结构的化合物。 已经发现，二十碳五烯酸和二十二碳六烯酸的二羟基体通常不是已知的（11,18-二羟基二十碳五烯酸（11,18-diHEPE），17,18-二羟基二十碳五烯酸（17,18-diHEPE ）等）具有抑制嗜中性粒细胞的活性，从而解决了对象。 本发明意外地显着地抑制了在急性炎症中发现的组织和嗜中性粒细胞的活化。 本发明的化合物是通常未知的化合物。 因此，提供了作为新治疗剂的效用。

公开(公告)号：US20090186145A1

公开(公告)日：2009-07-23

申请号：US12227951

申请日：2007-06-19

申请人： Sanshirou Saito ,  Toshiro Sato ,  Syuichi Kamo ,  Yousuke Isobe

发明人： Sanshirou Saito ,  Toshiro Sato ,  Syuichi Kamo ,  Yousuke Isobe

IPC分类号： A23J3/16 ,  A23L1/307 ,  A23L2/38

CPC分类号： A61K36/48 ,  A21D2/266 ,  A21D13/80 ,  A23L33/185 ,  A23V2002/00 ,  A61K36/185 ,  A23V2200/326 ,  A23V2200/3262 ,  A23V2250/5488 ,  A23V2250/0616 ,  A23V2250/5118 ,  A23V2250/5108

摘要： The present invention is intended to provide a composition for preventing or improving metabolic syndrome, which is safe and efficiently ingestible. Provided is a composition for reducing blood cholesterol level, improving blood HDL/LDL cholesterol ratio, reducing blood triglyceride level, reducing blood sugar level, controlling increase in liver weight, and/or reducing body weight, the composition containing soybean germ protein as an active ingredient. The composition according to the present invention improves blood cholesterol level, triglyceride, and glucose levels thereby contributing to health promotion.

摘要翻译： 本发明旨在提供一种用于预防或改善安全有效摄入的代谢综合征的组合物。 提供了含有大豆胚芽蛋白作为活性成分的组合物，其用于降低血液中胆固醇水平，提高血液HDL / LDL胆固醇比例，降低血液甘油三酯水平，降低血糖水平，控制肝脏重量增加和/或降低体重 成分。 根据本发明的组合物改善血液胆固醇水平，甘油三酯和葡萄糖水平，从而有助于促进健康。